Breast Cancer

Younger Breast Cancer Patients at Higher Risk for Osteoporosis

Younger Breast Cancer Patients at Higher Risk for Osteoporosis

By

Investigators found that incident osteopenia and osteoporosis are significantly higher in young survivors of breast cancer.

Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment

Lisinopril and Carvedilol May Reduce Cardiotoxicity During Adjuvant Trastuzumab Treatment

By

Among breast cancer patients on adjuvant trastuzumab, lisinopril and carvedilol reduced cardiotoxicity, but only for those in the anthracycline cohort.

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

Despite Breast-Conserving Surgery Eligibility, Nearly 50% of Women Chose Mastectomy

By

Researchers find that surgical decision making is often driven by factors beyond extent of disease.

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

Risk Score Identifies Adjuvant Chemotherapy Toxicity Risk in Elderly Patients With Breast Cancer

By

CARB-BC predicted grade 3 to 5 adverse events, dose modifications, and hospitalizations.

Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer

Immune Marker Identified as Prognostic in Triple-Negative Breast Cancer

By

The immune marker PD1 may be prognostic for survival in patients with TNBC who achieve a pathologic complete response after neoadjuvant therapy.

Rates of Adverse Events Similar Regardless of IMRT Boost Type

Rates of Adverse Events Similar Regardless of IMRT Boost Type

By

The rates of adverse events seen across dose schedule type for patients who underwent IMRT were roughly similar.

TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes

TAILORx Shows Black Women With Breast Cancer Have Worse Clinical Outcomes

By

Black women with the most common type of breast cancer had worse clinical outcomes compared with white women, despite receiving similar systemic therapy.

Alpelisib Plus Fulvestrant Continues to Show Improved PFS in <i>PIK3CA</i>-Mutant, HR+, HER2- Advanced Breast Cancer

Alpelisib Plus Fulvestrant Continues to Show Improved PFS in PIK3CA-Mutant, HR+, HER2- Advanced Breast Cancer

By

Alpelisib plus fulvestrant consistently resulted in prolonged PFS among patients with HR-positive, HER2-negative advanced breast cancer who also had PIK3CA mutations.

Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer

Partial-Breast Irradiation Not Equal to Whole-Breast Irradiation in Early-Stage Breast Cancer

By

Partial-breast irradiation failed to meet protocol-defined measures for equivalence.

High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer

High CTC Count Favors Chemotherapy in First-Line ER+, HER2- Metastatic Breast Cancer

By

CTC count may help guide the decision between first-line chemotherapy or endocrine therapy in ER-positive, HER-negative metastatic breast cancer.

Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS

Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS

By

The extension of adjuvant anastrozole to 10 years of treatment showed higher rates of DFS and distant DFS, but did not improve overall survival.

Palbociclib Plus Letrozole Did Not Show Clinical Benefit in PALLET Trial

Palbociclib Plus Letrozole Did Not Show Clinical Benefit in PALLET Trial

By

The addition of palbociclib to letrozole did not show clinical benefit as a neoadjuvant therapy, but did enhance the suppression of malignant cell proliferation.

Low-Dose Tamoxifen Prevents Recurrence of Breast Intraepithelial Neoplasia

Low-Dose Tamoxifen Prevents Recurrence of Breast Intraepithelial Neoplasia

By

The results of the TAM-01 phase III trial suggest that the dose of tamoxifen can be lowered to achieve better safety without compromising efficacy.

Age, Grade, Stage Predicted Receipt of Adjuvant Chemotherapy in Elderly Patients With Breast Cancer

Age, Grade, Stage Predicted Receipt of Adjuvant Chemotherapy in Elderly Patients With Breast Cancer

By

Adjuvant chemotherapy was linked to improved overall survival in older adults with breast cancer.

Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo

Study Identifies Patients With Breast Cancer Who Don't Benefit From Adjuvant Chemo

By

A meta-analysis showed that breast cancer patients who have a pathologic complete response after neoadjuvant chemotherapy may not benefit from adjuvant chemotherapy.

Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial

Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial

By

Adjuvant trastuzumab emtansine showed improved invasive disease-free survival compared with trastuzumab in HER2-positive early breast cancer.

Mutations Identified Distinguishing Metastatic from Early-Stage HR+/HER2- Breast Cancer

Mutations Identified Distinguishing Metastatic from Early-Stage HR+/HER2- Breast Cancer

By

New research may help identify new candidate targets and stratify patients eligible for innovative therapies.

Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer

Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer

By

Adjuvant capecitabine provided no survival benefit for patients with early triple-negative breast cancer, except for those with nonbasal-like disease.

CAR-T Trial for Triple-Negative Breast Cancer Under Way

CAR-T Trial for Triple-Negative Breast Cancer Under Way

By

Researchers reported early findings of a trial evaluating chimeric antigen receptor T-cell therapy for a subset of triple-negative breast cancer patients.

Insights into the Landscape of the Breast Tumor Microenvironment

Insights into the Landscape of the Breast Tumor Microenvironment

By

Valuable insights revealed from the characterization of the tumor microenvironment of thousands of early and metastatic breast cancer cells.

IMpassion130: PD-L1 Immune Cells Predictive of Survival Outcomes in Advanced TNBC

IMpassion130: PD-L1 Immune Cells Predictive of Survival Outcomes in Advanced TNBC

By

PD-L1 expression by tumor-infiltrating immune cells was found to be the most predictive biomarker for survival outcomes for patients with advanced TNBC in the IMpassion130 trial.

Researchers Identify Genomic Alterations That Drive Disease Progression and Endocrine Resistance in Invasive Lobular Cancer

Researchers Identify Genomic Alterations That Drive Disease Progression and Endocrine Resistance in Invasive Lobular Cancer

By

Results from the largest metastatic ILC series in which matched primary tumor and metastases samples were interrogated.

2018 San Antonio Breast Cancer Symposium: What to Expect

By

The San Antonio Breast Cancer Symposium will take place from December 4-8 at the Henry B. Gonzalez Convention Center in Texas.

Metabolite Profile Predisposes Patients With Breast Cancer to Weight Gain

Metabolite Profile Predisposes Patients With Breast Cancer to Weight Gain

By

Sixty patients with early stage breast cancer who underwent surgery and then were treated per national guidelines were included in the pilot study.

Statins Repurposed to Slow Proliferation in Metastatic Breast Cancer Cells

Statins Repurposed to Slow Proliferation in Metastatic Breast Cancer Cells

By

The findings suggest the consideration of long-term use of statins for patients with breast cancer.

Gender-Based Differences in Chemotherapy: Efficacy and Safety

Gender-Based Differences in Chemotherapy: Efficacy and Safety

By

Women and men were found to react differently to treatment with chemotherapy, although gender-based survival differences were not observed.

Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up

Liquid Biopsy as a Surveillance Tool for Breast Cancer Follow-Up

By

High-risk early breast cancer patients with circulating tumor cells 2 years after chemotherapy had greater risk of recurrence. Possible interventions are needed.

Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype

Conditional 10-Year Breast Cancer Recurrence Rates Decline Regardless of Subtype

By

Among 4 specific breast cancer stages, T2N1 cancers showed the highest risk for local recurrence, regional recurrence, and distant metastases within 10 years from diagnosis.

Moving Targets: Off-Label Prescribing of Targeted Therapies

Moving Targets: Off-Label Prescribing of Targeted Therapies

By

By way of the TAPUR study, researchers are attempting to evaluate the activity of targeted therapies when they are used in an off-label setting.

Higher Sensitivity With 1-View Digital Breast Tomosynthesis for Breast Cancer Detection

Higher Sensitivity With 1-View Digital Breast Tomosynthesis for Breast Cancer Detection

By

One-view digital breast tomosynthesis with a reduced compression force detected breast cancer with higher sensitivity and lower specificity than 2-view digital mammography.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs